Ventyx Biosciences, Inc.

Biotechnology • Healthcare • San Diego, CA, United States • VTYX (NMS)

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

760 593 4832 12790 El Camino Real, San Diego, CA 92130, United States

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Ventyx Biosciences (NASDAQ:VTYX) Shares Down 6.1% - Time to Sell? - MarketBeat

MarketBeat • Jan 5

Analysts Bullish as Ventyx Biosciences (VTYX) Advances Its Clinical and Strategic Initiatives - Yahoo Finance

Yahoo Finance • Dec 21

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX - PR Newswire

PR Newswire • Jan 1

Ventyx shares soar after study suggests cardiovascular benefits for experimental drug - BioPharma Dive

BioPharma Dive • Oct 23

Ventyx's CV drug reduces cardio risk biomarker by nearly 80% in 1st week of phase 2 study - Fierce Biotech

Fierce Biotech • Oct 23

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Ventyx Biosciences, Inc. had layoffs?

No layoff events have been recorded for Ventyx Biosciences, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Ventyx Biosciences, Inc. have?

Ventyx Biosciences, Inc. has approximately 83 employees.

What industry is Ventyx Biosciences, Inc. in?

Ventyx Biosciences, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Ventyx Biosciences, Inc. a publicly traded company?

Yes, Ventyx Biosciences, Inc. is publicly traded under the ticker symbol VTYX on the NMS. The company has a market capitalization of approximately $0.65 billion.

Where is Ventyx Biosciences, Inc. headquartered?

Ventyx Biosciences, Inc. is headquartered in San Diego, CA, United States at 12790 El Camino Real, San Diego, CA 92130, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.